In 2004, Warner Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities in connection with its illegal and fraudulent promotion of unapproved uses for its drug Neurontin. The U.S. department of Justice report that 'Warner-Lambert's strategic marketing plans, as well as other evidence, show that Neurontin was aggressively marketed to treat a wide array of ailments for which the drug was not approved'. They go on to add that Warner-Lambert promoted Neurontin even when scientific studies had shown that it was not effective and for uses that had been specifically rejected by the FDA.
- BBC News Drugs Giants Merge Accessed 12th February 2008
- Business Insights Patient Power: The shift towards more informed, more powerful consumers of drugs Accessed 5th February 2008
- U.S. Department of Justice WARNER-LAMBERT TO PAY $430 MILLION TO RESOLVE CRIMINAL & CIVIL HEALTH CARE LIABILITY RELATING TO OFF-LABEL PROMOTION Accessed 12th february 2008